Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 3/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024131 | 0.89 | ECE1 (0.34) | ECE1BUB1MAPTAKR1B1 | |
| SCHEMBL3024357 | 0.87 | MAPT (0.48) | ECE1BUB1MAPT | |
| SCHEMBL3023675 | 0.85 | NOD2 (0.43) | MAPT | |
| SCHEMBL3028523 | 0.84 | NTRK1 (0.38) | CCR2NTRK1CCR9AGTR1AGTR2 | |
| SCHEMBL3034236 | 0.82 | CYP2C9 (0.48) | — | |
| SCHEMBL3028594 | 0.80 | MAPT (0.37) | CCR2AGTR1AGTR2MAPTAKR1B1 | |
| SCHEMBL3039673 | 0.80 | MAP2K1 (0.42) | NTRK1ECE1MAPT | |
| SCHEMBL12083414 | 0.79 | MAP2K1 (0.50) | — | |
| SCHEMBL12085726 | 0.75 | KCNH2 (0.40) | ECE1MAPT | |
| SCHEMBL12083411 | 0.75 | KCNH2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164850-B1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH INC (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2164850-B1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2164850-A2 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | Genetech, Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008157179-A2 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | MKI67, CCNI, CDKN1A | CCR2 1868/4885NTRK1 983/4885CCR9 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.